Skip to main content
. 2021 Aug 12;14(8):791. doi: 10.3390/ph14080791

Figure 7.

Figure 7

Percentage of cell viability from the biological study in the breast cancer cell line MDA-MB-231, (A) gefitinib; (B) lapatinib; (C) terazosin; (D) alfuzosin; (E) prazosin; (F) irinotecan; and (G) quinacrine. All assays were performed in triplicate.